Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New study tests RSV prevention in vulnerable infants

NCT ID NCT06851806

First seen Nov 17, 2025 · Last updated Jun 16, 2026 · Updated 27 times

Summary

This study checks the safety of a monthly injection called palivizumab in infants and children under 24 months who are at high risk for severe RSV disease. About 138 participants will receive up to 5 injections over the study period. The goal is to see how safe the drug is and track any side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Hyderabad, 500084, India

  • Research Site

    NOT_YET_RECRUITING

    Pune, 411006, India

Conditions

The condition(s) this trial relates to.

respiratory syncytial virus infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.